Listed

Becton Dickinson & Co: Form 10-Q for the period ended Mar 31, 2016

Filed with the SEC on May 6, 2016 and accepted by EDGAR at May 6, 2016, 14:08 ET.

Share

Management's discussion and analysis

As filed, 42,327 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon two principal business segments, BD Medical (“Medical”) and BD Life Sciences (“Life Sciences”).

BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: Europe; EMA (which includes the Commonwealth of Independent States, the Middle East and Africa); Greater Asia (which includes Japan and Asia Pacific); Latin America (which includes Mexico, Central America, the Caribbean, and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and certain countries within Asia Pacific. We are primarily focused on certain countries whose healthcare systems are expanding, in particular, China and India.

Acquisition of CareFusion

On March 17, 2015, BD acquired a 100% interest in CareFusion Corporation ("CareFusion"). CareFusion’s operating results were included in BD’s consolidated results of operations beginning on April 1, 2015 and as such, the consolidated results of operations for the prior-year periods ended March 31, 2015 referenced in the commentary provided further below did not include CareFusion's results. CareFusion operates as part of our Medical segment.

Overview of Financial Results and Financial Condition

For the three months ended March 31, 2016, revenues increased 49.6% to $3.067 billion from the prior year, which primarily reflected an impact of $1.017 billion from the inclusion of CareFusion revenues in the current quarter’s results. Revenue growth for BD's legacy operations was primarily driven by volume, and to a lesser extent price, but was offset by the impact of unfavorable foreign currency translation.

The current-year period’s total revenues reflected the following:

  • Second quarter Medical segment revenue growth reflected the inclusion of CareFusion’s sales in the current-year period's results, as well as continued growth attributable to the segment's BD legacy products in the Medication and Procedural Solutions, Diabetes Care and Pharmaceutical Systems units.
  • Life Sciences segment revenue growth in the second quarter reflected growth in the Preanalytical Systems and Diagnostic Systems units.
  • Worldwide sales of safety-engineered products reflected the inclusion of CareFusion's sales of safety-engineered products in the current year's quarter, as well as growth that was attributable to BD's legacy safety-engineered products. Second quarter sales in the United States of safety-engineered devices of $443 million increased 50.7% and second quarter international sales of safety-engineered devices of $290 million grew 13.1% over the prior year’s period, inclusive of an estimated 12.0% unfavorable impact due to foreign currency translation.

We continue to invest in research and development, geographic expansion, and new product promotions to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products, and continue to improve operating efficiency and organizational effectiveness, including through the integration of CareFusion. While the economic environment for the healthcare industry has stabilized, pricing pressures continue for some of our products. Healthcare utilization and research spending has stabilized and slightly improved in the United States; however, any destabilization in the future could adversely impact our U.S. businesses. Additionally, macroeconomic challenges in Europe continue to constrain healthcare utilization, although we currently view the environment as stable. In emerging markets, the Company’s growth is dependent primarily on government funding for healthcare systems.

Our financial position remains strong, with cash flows from operating activities totaling $1.020 billion in the first six months of fiscal year 2016. At March 31, 2016, we had $1.7 billion in cash and equivalents and short-term investments. We continued to return value to our shareholders in the form of dividends. During the first six months of fiscal year 2016, we paid cash dividends of $280 million. No shares were repurchased during the first six months of fiscal year 2016.

Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. The ongoing relative strength of the U.S. dollar resulted in an unfavorable foreign currency translation impact to our revenue growth during the quarter. We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Foreign currency-neutral ("FXN") information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

Results of Operations

Revenues

Medical Segment

The following summarizes second quarter Medical revenues by organizational unit, as well as second quarter Medical sales of safety-engineered products:

(Millions of dollars) Three months ended March 31, 2016 2015 Total Change Estimated FX Impact FXN Change
Medication and Procedural Solutions $831 $565 47.2% (6.0)% 53.2%
Medication Management Solutions 536 — NM NM NM
Diabetes Care 243 247 (1.3)% (4.9)% 3.6%
Pharmaceutical Systems 311 294 5.6% (5.4)% 11.0%
Respiratory Solutions 213 — NM NM NM
Deferred revenue adjustment (A) (4) — NM NM NM
Total Medical Revenues $2,131 $1,106 92.8% (6.4)% 99.2%
Medical segment safety-engineered products $465 $281 65.5% (6.1)% 71.6%

(A) In accordance with U.S. GAAP business combination accounting rules, CareFusion’s deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

Overall Medical segment revenue growth in the current year's quarter largely reflected the inclusion of CareFusion’s sales in the current period’s results. Revenue growth in our Medication and Procedural Solutions unit, which includes our former Medical Surgical Systems unit, additionally reflected growth in sales of safety-engineered and infusion therapy products. Revenue growth for the Diabetes Care unit was driven by sales of pen needles and syringes. The Pharmaceutical Systems unit's revenue growth reflected sales of self-injection systems and the earlier than anticipated placement of orders within the current fiscal year.

Medical segment revenues and sales of safety-engineered products for the six-month period were as follows:

(Millions of dollars) Six months ended March 31, 2016 2015 Total Change Estimated FX Impact FXN Change
Total Medical Revenues $4,185 $2,177 92.2% (7.8)% 100.0%
Medical segment safety-engineered products $932 $577 61.6% (6.4)% 68.0%

Medical segment operating income for the three-month and six-month periods were as follows:

(Millions of dollars) Three months ended March 31, 2016 2015 Six months ended March 31, 2016 2015
Medical segment operating income $513 $328 $978 $632
Segment operating income as % of Medical revenues 24.1% 29.7% 23.4% 29.0%

The Medical segment's operating income is driven by its performance with respect to gross profit margin and other operating expenses. Gross profit margin was lower in the current quarter as compared with the second quarter of 2015 primarily due to amortization of $116 million for intangible assets acquired in the CareFusion transaction. This unfavorable impact on gross margin was partially offset by lower manufacturing costs resulting from continuous improvement projects improving the efficiency of our operations. Selling and administrative expense for the second quarter of fiscal year 2016 was higher due to depreciation of fixed assets acquired in the CareFusion acquisition. Research and development expenses for the quarter increased $57 million, or 148% above the prior year’s period, primarily due to the inclusion of CareFusion’s costs in the current period’s results.

Life Sciences Segment

The following is a summary of second quarter Life Sciences revenues by organizational unit, as well as second quarter Life Sciences sales of safety-engineered products:

(Millions of dollars) Three months ended March 31, 2016 2015 Total Change Estimated FX Impact FXN Change
Preanalytical Systems $340 $339 0.4% (5.3)% 5.7%
Diagnostic Systems 319 318 0.4% (4.2)% 4.6%
Biosciences 277 289 (4.1)% (3.6)% (0.5)%
Total Life Sciences Revenues $936 $945 (1.0)% (4.4)% 3.4%
Life Sciences segment safety-engineered products $268 $269 (0.5)% (5.1)% 4.6%

Life Sciences segment revenue growth for the quarter was driven by the Preanalytical Systems and Diagnostic Systems units. The Preanalytical Systems unit's revenue growth was driven by U.S. sales of safety-engineered products as well as by sales in Europe and emerging markets. The Diagnostic Systems unit's second quarter revenue growth rates reflected growth in sales of microbiology products. The Diagnostic Systems unit's second quarter revenues also benefited from a late start to the influenza season compared with the prior-year period. The Biosciences unit’s second quarter revenues were relatively flat compared with the prior-year period. Introductions of new products, continued increased demand for high-parameter instruments and growth in research reagents was offset by unfavorable timing of orders in Europe and delayed clinical tenders in Africa.

Life Sciences segment total revenues and sales of safety-engineered products for the six-month period were as follows:

(Millions of dollars) Six months ended March 31, 2016 2015 Total Change Estimated FX Impact FXN Change
Total Life Sciences Revenues $1,869 $1,925 (2.9)% (5.4)% 2.5%
Life Sciences segment safety-engineered products $538 $547 (1.6)% (5.9)% 4.3%

Life Sciences segment operating income for the three-month and six-month periods were as follows:

(Millions of dollars) Three months ended March 31, 2016 2015 Six months ended March 31, 2016 2015
Life Sciences segment operating income $202 $200 $404 $413
Segment operating income as % of Life Sciences revenues 21.6% 21.1% 21.6% 21.5%

The Life Sciences segment's operating income is driven by its performance with respect to gross profit margin and other operating expenses. Gross profit margin in the second quarter of fiscal year 2016 was in line with the second quarter of 2015 as the unfavorable impact of foreign currency translation was offset by margin gains primarily resulting from operational efficiencies. Selling and administrative expense as a percentage of Life Sciences revenues in the second quarter of 2016 was also in line with the second quarter of 2015. Research and development expense in the second quarter of 2016 decreased by $4 million, or 5%, which was primarily influenced by the timing of project spending.

Geographic Revenues

BD’s worldwide second quarter revenues by geography were as follows:

(Millions of dollars) Three months ended March 31, 2016 2015 Total Change Estimated FX Impact FXN Change
United States $1,719 $863 99.2% — 99.2%
International 1,349 1,188 13.5% (9.5)% 23.0%
Total Revenues $3,067 $2,051 49.6% (5.5)% 55.1%

U.S. revenues reflected growth from both segments. The Medical segment's U.S. revenues reflected the inclusion of CareFusion’s U.S. sales of approximately $806 million as well as growth in sales of the Medication and Procedural Solutions unit's infusion therapy products and the earlier than anticipated placement of orders within the fiscal year in the Pharmaceutical Systems unit, as previously discussed. U.S. Life Sciences revenue growth in the second quarter of fiscal year 2016 was driven by new product introductions, continued increased demand for high-parameter instruments and growth in research reagents in the Biosciences unit. U.S. Life Sciences revenue growth was also driven by the Diagnostic Systems unit's sales of microbiology products and molecular diagnostic platforms as well as by the Preanalytical Systems unit's sales of safety-engineered products. The Diagnostic Systems unit's second quarter revenues also benefited from a late start to the influenza season compared with the prior-year period.

In addition to the inclusion of CareFusion’s sales of approximately $211 million in the current year’s quarter, the Medical segment's international revenue growth reflected growth in the Medication and Procedural Solutions unit's sales of safety-engineered products, particularly in China. International revenue growth in the Medical segment also benefited from the earlier placement of orders in the Pharmaceutical Systems unit, as previously discussed. The Life Sciences segment's second quarter international revenue growth reflected growth of the Preanalytical Systems unit's sales of safety-engineered products in Western Europe and Asia Pacific and of the Diagnostic Systems unit's sales of microbiology products in Western Europe and Latin America. International revenue growth in the Life Sciences segment was negatively impacted by both the unfavorable timing of orders in Europe and delayed clinical tenders in Africa for the Biosciences unit.

Effective October 1, 2015, we changed the composition of countries that we define as emerging markets within the Asia Pacific region. On this redefined basis, emerging market revenues for the second quarter were $443 million, compared with $428 million in the prior year’s quarter, and included an estimated $46 million unfavorable impact due to foreign currency translation. Revenue growth in emerging markets for the second quarter was primarily driven by the inclusion of CareFusion's sales in the period.

Specified Items

Reflected in the financial results for the three and six-month periods of fiscal years 2016 and 2015 are the following specified items:

(Millions of dollars) Three months ended March 31, 2016 2015 Six months ended March 31, 2016 2015
Financing costs (A) $— $58 $— $102
Transaction costs (A) — 33 — 43
Integration costs (A) 40 18 75 31
Restructuring costs (A) 64 62 149 62
Purchase accounting adjustments (B) 115 9 268 27
Litigation-related charge (C) — — — 12
Total specified items 218 180 492 277
Tax impact of specified items 85 77 164 108
After-tax impact of specified items $134 $102 $329 $169

(A) Represents financing, transaction, integration and restructuring costs associated with the CareFusion acquisition and portfolio rationalization. The financing costs were recorded in Interest expense. The transaction, integration and restructuring costs were recorded in Acquisitions and other restructurings.

(B) Primarily represents non-cash amortization expense associated with acquisition-related identifiable intangible assets, including $116 million and $246 million in the current quarter and six-month period, respectively, related to CareFusion. BD’s amortization expense is primarily recorded in Costs of products sold. The adjustments in the three and six-month periods of fiscal year 2016 also include a net decrease in the fair value of certain contingent consideration liabilities of $22 million that was recognized in the second quarter. The adjustment for the three and six months ended March 31, 2015 additionally reflected a pre-tax acquisition-date accounting gain of $9 million on a previously held investment.

(C) Represents a charge for plaintiff attorneys’ fees, recorded in Selling and administrative expense, associated with the antitrust and false advertising lawsuit RTI filed against BD. For further discussion, refer to Note 5 in the Notes to Condensed Consolidated Financial Statements.

Gross Profit Margin

Gross profit margin for the three and six-month periods of fiscal year 2016 compared with the prior-year periods in 2015 reflected the following impacts:

Three-month period Six-month period
March 31, 2015 gross profit margin % 51.0% 51.0%
CareFusion acquisition-related asset depreciation and amortization (4.0)% (4.4)%
Foreign currency translation (0.2)% (0.6)%
Operating performance 1.6% 1.8%
March 31, 2016 gross profit margin % 48.4% 47.8%

The operating performance impacts for the current year's quarter and six-month period reflected lower manufacturing costs resulting from continuous improvement projects improving the efficiency of our operations.

Operating Expenses

A summary of operating expenses for the three and six months ended March 31, 2016 and 2015 is as follows:

(Millions of dollars) Three months ended March 31, 2016 2015 Increase (decrease) in basis points 2016 Six months ended March 31, 2015 Increase (decrease) in basis points
Selling and administrative expense $732 $511 $1,480 $1,055
% of revenues 23.9% 24.9% (100) 24.5% 25.7% (120)
Research and development expense $182 $129 $369 $258
% of revenues 5.9% 6.3% (40) 6.1% 6.3% (20)
Acquisitions and other restructurings $104 $113 $225 $136

Selling and administrative expense

Selling and administrative expense as a percentage of revenues in the current year’s three and six-month periods reflected cost synergies resulting from the CareFusion acquisition and favorable foreign currency translation, partially offset by the depreciation of fixed assets acquired in the CareFusion acquisition. Selling and administrative expense as a percentage of revenues in the prior-year six-month period reflected a charge of $12 million relating to the RTI litigation matter, as previously discussed.

Research and development expense

The increases in research and development expense for three and six-month periods of fiscal year 2016 compared with the prior-year periods in 2015 primarily reflected the inclusion of CareFusion’s research and development expenses in the current periods' results. The decreases in research and development expense as a percentage of revenues in the current year's periods reflected the timing of project spending.

Acquisitions and other restructurings

Costs relating to acquisitions and other restructurings in the three and six-month periods represented transaction, integration and restructuring costs associated with the CareFusion acquisition and portfolio rationalization. The transaction and integration costs specifically included advisory, legal, and other costs incurred in connection with the CareFusion acquisition. For further disclosures regarding the restructuring costs, refer to Note 11 in the Notes to Condensed Consolidated Financial Statements.

Net Interest Expense

The components of net interest expense for the three and six-month periods were as follows:

(Millions of dollars) Three months ended March 31, 2016 2015 Six months ended March 31, 2016 2015
Interest expense $(99) $(91) $(196) $(167)
Interest income 3 8 9 19
Net interest expense $(96) $(83) $(187) $(149)

The increases in interest expense for the three and six-month periods of fiscal year 2016 compared with the prior year's periods primarily reflected increased financing costs associated with the CareFusion acquisition, partially offset by favorable amortization of the acquisition-date fair value-step recorded on CareFusion’s long-term debt as well as by favorable comparison to the prior-year periods, which included commitment fees for a bridge loan facility that was terminated in March 2015.

The decreases in interest income for the three and six-month periods of fiscal year 2016 compared with the prior year’s periods primarily reflected lower cash levels outside of the United States and lower investment gains on assets related to our deferred compensation plans. The offsetting movements in the deferred compensation plan liability were recorded in Selling and administrative expense.

Income Taxes

The income tax rates for the three and six-month periods are provided below. The tax benefits of the specified items shown earlier reduced the current and prior-year periods' income tax rates as the tax benefits on these specified items were primarily incurred in higher tax jurisdictions.

Three months ended March 31, 2016 2015 Six months ended March 31, 2016 2015
Effective income tax rate 10.0% 3.9% 11.7% 11.4%
Favorable impact, in basis points, from tax benefits of specified items 1,060 1,740 930 980

Net Income and Diluted Earnings per Share

Net Income and Diluted Earnings per Share for the three and six-month periods were as follows:

Three months ended March 31, 2016 2015 Six months ended March 31, 2016 2015
Net Income (Millions of dollars) $338 $216 $567 $452
Diluted Earnings per Share $1.56 $1.08 $2.62 $2.28
Unfavorable impact-specified items $(0.62) $(0.51) $(1.52) $(0.85)
Unfavorable impact-foreign currency translation $(0.14) $(0.40)

Liquidity and Capital Resources

The following table summarizes our consolidated statement of cash flows:

(Millions of dollars) Net cash provided by (used for) Six months ended March 31, 2016 2015
Operating activities $1,020 $514
Investing activities $(170) $(7,829)
Financing activities $(576) $7,392

Net Cash Flows from Operating Activities

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs for the remainder of fiscal year 2016. Normal operating needs in fiscal year 2016 include working capital, capital expenditures, and cash dividends. The change in net cash provided by operating activities was primarily attributable to income from continuing operations, as adjusted for depreciation and amortization and other non-cash items. The current period change in operating assets and liabilities was a net use of cash and primarily reflected lower levels of accounts payable and accrued expenses and higher levels of accounts receivables. Net cash provided by operating activities in the first six months of fiscal year 2015 was reduced by a discretionary cash contribution of $40 million to fund our pension obligation.

Net Cash Flows from Investing Activities

Capital expenditures were $258 million in the first six months of fiscal year 2016 compared with $252 million in the prior-year period. Net cash used for investing activities in the current-year period reflected $111 million of proceeds from the sale of a non-core asset. Net cash used for investing activities in the prior-year period reflected cash outflows of $8.3 billion related to our acquisition of CareFusion and other smaller acquisitions occurring in the prior-year period. These cash outflows in the prior-year period were partially offset by sales of investments of $813 million due to the maturities of time deposits in Europe, Latin America and Asia Pacific.

Net Cash Flows from Financing Activities

Net cash used for financing activities in the first six months of fiscal year 2016 included a payment of $300 to reduce the balance of our commercial paper program. Net cash provided by financing activities in the prior-year period included the proceeds from $6.2 billion of notes issued in December 2014 as well as $1.5 billion total proceeds from net borrowings under commercial paper programs and a term loan facility. These proceeds were used to finance the completion of our acquisition of CareFusion in March 2015.

Debt-related Activities

Certain measures relating to our total debt were as follows:

(Millions of dollars) March 31, 2016 September 30, 2015
Total debt $12,515 $12,822
Short-term debt as a percentage of total debt 13.2% 11.3%
Weighted average cost of total debt 3.4% 3.3%
Total debt as a percentage of total capital* 58.1% 59.4%

* Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.

The ratio of short-term debt as a percentage of total debt at March 31, 2016 reflected the reclassification, from long-term debt to short-term debt, of $500 million of 1.75% notes due on November 8, 2016. The ratio of debt as a percentage of total capital at September 30, 2015 reflects adjustments to the condensed consolidated balance sheet resulting from our adoption of revised presentation requirements relating to deferred taxes. Additional information regarding this adoption is provided in Note 2 in the Notes to Condensed Consolidated Financial Statements.

Cash and Short-term Investments

At March 31, 2016, total worldwide cash and short-term investments were approximately $1.7 billion, of which $1.05 billion was held in jurisdictions outside of the United States. We regularly review the amount of cash and short-term investments held outside the United States and currently intend to use such amounts to fund our international operations and their growth initiatives. In addition, if these amounts were repatriated from foreign jurisdictions to the United States, there could be adverse tax consequences.

Credit Facilities

We have in place a commercial paper borrowing program which is available to meet our short-term financing needs, including working capital requirements. In February 2016, we increased the size of this program by $500 million so that it allows us to issue a maximum of $1.5 billion in notes. Borrowings outstanding under this program were $400 million at March 31, 2016, which reflected a payment of $300 million during the second quarter of fiscal year 2016, as previously discussed.

In January 2016, we replaced an existing $1 billion syndicated credit facility with a $1.5 billion syndicated credit facility that has an expiration date of January 2021. There were no borrowings outstanding under this credit facility at March 31, 2016. The credit facility, under which we may issue up to $100 million in letters of credit, provides backup support for our commercial paper program and can also be used for other general corporate purposes. It includes a provision that enables BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2 billion. The credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio of not less than 5-to-1 for the most recent four consecutive fiscal quarters. We were in compliance with this covenant as of March 31, 2016. We also have informal lines of credit outside the United States.

Concentrations of Credit Risk

We continually evaluate our accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. We continually evaluate all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on our financial position or liquidity.

Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future – including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results – are forward-looking statements.

Forward-looking statements are based on our current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in our 2015 Annual Report on Form 10-K.

  • Weakness in the global economy and financial markets, and the potential adverse effect on the cost of operating our business, the demand for our products and services, the prices for our products and services due to increases in pricing pressure, or our ability to produce our products, including the impact on developing countries.
  • Deficit reduction efforts or other adverse changes in the availability of government funding for healthcare and research that could further weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
  • Risks relating to our acquisition of CareFusion, including our ability to successfully combine and integrate the CareFusion operations in order to obtain the anticipated benefits and costs savings from the transaction, and the significant additional indebtedness we incurred in connection with the financing of the acquisition and the impact this increased indebtedness may have on our ability to operate the combined company.
  • The consequences of the Patient Protection and Affordable Care Act in the United States, which implemented an excise tax on U.S. sales of certain medical devices (which has been suspended until January 1, 2018), and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect our business.
  • Future healthcare reform in the countries in which we do business that may involve changes in government pricing and reimbursement policies or other cost containment reforms.
  • Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment. For example, changes to guidelines providing for increased cervical cancer screening intervals has and may continue to negatively impact sales of our Women’s Health and Cancer platform.
  • Changes in reimbursement practices of governmental or private third-party payers.
  • Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities and distribution networks. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption laws.
  • Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, trade barriers, restrictions on the ability to transfer capital across borders and expropriation of assets by a government.
  • Security breaches of our computer and communications systems or our products, including computer viruses, “hacking” and “cyber-attacks,” which could impair our ability to conduct business, result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of customers' patients, or result in product efficacy or safety concerns.
  • Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
  • Regional, national and foreign economic factors, including inflation, deflation, fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings.
  • New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls and licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
  • Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, in which there has been increased enforcement activity by the FDA. As a result of the CareFusion acquisition, we are operating under a consent decree with the FDA relating to our U.S. infusion pump business. The consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing products, recall products or take other actions, and we may be required to pay significant monetary damages if we fail to comply with any provision of the consent decree.
  • Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
  • The effects of events that adversely impact our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants) or our ability to source materials or components from suppliers (including sole-source suppliers) that are needed for such manufacturing, including pandemics, natural disasters, or environmental factors.
  • Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.
  • Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
  • Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.
  • Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
  • Pending and potential future litigation or other proceedings adverse to BD, including antitrust, product liability, environmental and patent infringement, and the availability or collectability of insurance relating to any such claims.
  • The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
  • The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
  • The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
  • Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
  • Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

Controls and procedures

As filed, 1,021 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of March 31, 2016. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. There were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2016 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

Risk factors

As filed, 172 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There were no material changes in the risk factors previously disclosed in Part I, Item 1A, of our 2015 Annual Report on Form 10-K during the period covered by this report.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-01-01 to 2016-03-31$3.07bnus-gaap:SalesRevenueNet
Revenue6 months2015-10-01 to 2016-03-31$6.05bnus-gaap:SalesRevenueNet
Cost of revenue3 months2016-01-01 to 2016-03-31$1.58bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2015-10-01 to 2016-03-31$3.16bnus-gaap:CostOfGoodsAndServicesSold
Research and development3 months2016-01-01 to 2016-03-31$182.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2015-10-01 to 2016-03-31$369.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2016-01-01 to 2016-03-31$732.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2015-10-01 to 2016-03-31$1.48bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-01-01 to 2016-03-31$466.0mus-gaap:OperatingIncomeLoss
Operating income6 months2015-10-01 to 2016-03-31$818.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-01-01 to 2016-03-31$99.0mus-gaap:InterestExpense
Interest expense6 months2015-10-01 to 2016-03-31$196.0mus-gaap:InterestExpense
Income tax3 months2016-01-01 to 2016-03-31$38.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2015-10-01 to 2016-03-31$75.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-01-01 to 2016-03-31$338.0mus-gaap:NetIncomeLoss
Net income6 months2015-10-01 to 2016-03-31$567.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-01-01 to 2016-03-31$1.56us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2015-10-01 to 2016-03-31$2.62us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-01-01 to 2016-03-31$1.59us-gaap:EarningsPerShareBasic
Basic EPS6 months2015-10-01 to 2016-03-31$2.67us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-01-01 to 2016-03-31216,538,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2015-10-01 to 2016-03-31216,695,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2015-10-01 to 2016-03-31$1.02bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2015-10-01 to 2016-03-31$258.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2015-10-01 to 2016-03-31$280.0mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2016-03-31$1.70bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-03-31$6.61bnus-gaap:AssetsCurrent
Total assetsAt period end2016-03-31$26.24bnus-gaap:Assets
Current liabilitiesAt period end2016-03-31$4.38bnus-gaap:LiabilitiesCurrent
Long-term debtAt period end2016-03-31$10.86bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2016-03-31$1.65bnus-gaap:DebtCurrent
Shareholders' equityAt period end2016-03-31$7.67bnus-gaap:StockholdersEquity
Shares outstandingAt period end2016-03-31212,202,004 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001628280-16-015791. Last ingested by Listed: Nov 11, 2026, 03:43 ET. Listed shows no prices and gives no investment advice.